AI Analysis | Feedback

Here are 1-2 brief analogies for Veru:

• A specialized biotech, like a mini-Genentech, focused on developing new cancer treatments.
• A bit like a miniature Johnson & Johnson, balancing a niche medical device business (female condoms) with an ambitious oncology drug development pipeline.

AI Analysis | Feedback

• FC2 female condom/internal condom: A commercial product offering dual protection against unintended pregnancy and sexually transmitted infections.
• Enobosarm: An oral selective androgen receptor agonist in Phase III clinical trial for AR+ ER+ HER2- metastatic breast cancer.
• Sabizabulin (for metastatic breast cancer): A drug candidate in Phase IIb clinical trial for AR+ ER+ HER2- metastatic breast cancer.
• Enobosarm + abemaciclib combination therapy: A combination therapy in Phase III clinical trial for AR+ ER+ HER2- metastatic breast cancer.
• Sabizabulin + enobosarm combination therapy: A combination therapy in Phase II clinical trial for metastatic triple negative breast cancer.
• Sabizabulin (for prostate cancer): A drug candidate in Phase II clinical trial for metastatic castration and androgen receptor targeting agent resistant prostate cancer.
• VERU-100: A GnRH antagonist peptide injection in Phase II clinical trial for advanced hormone sensitive prostate cancer.
• Zuclomiphene Citrate: A drug candidate in Phase II clinical trial for treating hot flashes.
• Sabizabulin (for SARS-CoV-2/ARDS): A drug candidate in Phase III clinical trial for SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome.
• New drug formulation for LUTS: A new drug formulation being developed for lower urinary tract symptoms from an enlarged prostate.

AI Analysis | Feedback

Veru (VERU) sells its commercial products, specifically the FC2 female condom/internal condom, primarily to organizational customers. These include:

• Governmental and Intergovernmental Organizations: Ministries of health, government health agencies, and U.N. agencies.
• Nonprofit Organizations: Various nonprofit entities.
• Commercial Partners: Other commercial entities that partner with Veru for distribution or sales.

AI Analysis | Feedback

AI Analysis | Feedback

Mitchell S. Steiner, M.D., F.A.C.S. Chairman, President, and Chief Executive Officer

Dr. Steiner has served as President and Chief Executive Officer of Veru Inc. since October 2016 and as Chairman of the Board since March 2018. He was a co-founder of Aspen Park Pharmaceuticals, Inc., where he served as Chief Executive Officer, President, and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, he was a consultant and then the President, Urology at OPKO Health, Inc., with responsibilities for the launch, marketing, sales, and reimbursement of the 4Kscore prostate cancer test. Dr. Steiner also co-founded GTx, Inc., a men's health and oncology public company, serving as its Chief Executive Officer and Vice Chairman of the Board of Directors from 1997 to 2014. He is a Board Certified Urologist and a Fellow of the American College of Surgeons. He received his M.D. from the University of Tennessee.

Michele Greco Chief Financial Officer and Chief Administrative Officer

Ms. Greco holds the positions of Chief Financial Officer and Chief Administrative Officer at Veru Inc. She is also the Principal Accounting Officer.

Harry Fisch, M.D., F.A.C.S. Vice Chairman, Chief Corporate Officer

Dr. Fisch has served as a director of Veru Inc. since October 2016, as Vice Chairman of the Board since March 2018, and as Chief Corporate Officer since January 2018. He co-founded Aspen Park, where he was Chairman of the Board and Chief Scientific Officer from July 2014 to October 2016. Since 1994, Dr. Fisch has been the Chief Executive Officer and President of Millennium Sciences, Inc.

K. Gary Barnette, Ph.D. Chief Scientific Officer

Dr. Barnette is the Chief Scientific Officer of Veru Inc. Before joining Veru, he was Senior Vice President of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services, LLC for six years, overseeing drug development strategies across various therapeutic areas. From 2000 to 2012, Dr. Barnette held several roles at GTx, Inc., including Vice President, Clinical Development Strategy. He previously served as a Clinical Pharmacology and Biopharmaceutics Reviewer at the U.S. FDA. Dr. Barnette earned his Ph.D. in Basic Pharmaceutical Sciences from West Virginia University, School of Pharmacy.

Gary Bird, Ph.D. Executive Vice President, Quality and Regulatory Affairs

Dr. Bird serves as the Executive Vice President of Quality and Regulatory Affairs at Veru Inc.

AI Analysis | Feedback

The key risks to Veru's business revolve primarily around the success of its lead drug candidate, enobosarm, in clinical trials and its financial viability to see these through to commercialization.

1. Clinical Trial Failure and Regulatory Non-Approval for Enobosarm

   Veru's future is heavily dependent on the successful completion of late-stage clinical trials for enobosarm, particularly for its new strategic focus on preserving lean muscle mass in patients taking GLP-1 agonists for weight loss. While Phase 2b results for enobosarm have shown a positive safety profile and the ability to preserve lean mass, success in Phase 3 is not guaranteed and could fail to replicate these results or face new challenges. The FDA has provided regulatory pathways, but success remains contingent on "flawless trial execution and future access to capital." A previous instance where an FDA advisory panel voted against the emergency use authorization of Veru's sabizabulin for COVID-19 highlights the inherent regulatory risks in the biopharmaceutical industry.

2. Financial Instability and Need for Future Capital

   Veru has reported ongoing net losses and negative cash flow from operations, indicating financial challenges. The company operates with a significant cash burn rate and has a limited cash runway, frequently necessitating dilutive financing rounds to fund its ambitious clinical development programs. While recent public offerings have strengthened its financial position, management acknowledges that continued clinical development will require additional capital. This financial instability poses a significant risk to the company's ability to complete trials and commercialize its drug candidates.

3. Intense Competition in the GLP-1 Obesity Market

   Veru has pivoted its primary focus to developing enobosarm as a companion therapy for GLP-1 agonists to prevent lean mass reduction in the booming obesity market. This market, however, is highly competitive, with numerous large pharmaceutical companies and other biotechs vying for market share. A breakthrough from a competitor with a superior or faster-to-market solution could jeopardize Veru's favorable market position and potential for market adoption, especially as existing GLP-1 treatments already offer significant weight loss.

AI Analysis | Feedback

AI Analysis | Feedback

The addressable markets for Veru's main products and services are as follows:

• FC2 female condom/internal condom: The global female condom market was valued at approximately USD 730 million in 2025. Another source states the market was valued at approximately USD 100 million globally in 2023, projected to grow at a CAGR of 5-7% over the next 5-10 years.
• Enobosarm, Sabizabulin, and Enobosarm + abemaciclib combination therapy for AR+ ER+ HER2- metastatic breast cancer: The market size for ER+/HER2- breast cancer in the United States was USD 6.759 billion in 2022, projected to grow during the forecast period (2026-2036). The US market size is expected to be USD 7.4 billion in 2025. The total metastatic HR+/HER2- breast cancer market size across the 7 Major Markets (7MM) was estimated to be nearly USD 9.1 billion in 2022.
• Sabizabulin + enobosarm combination therapy for metastatic triple negative breast cancer: The global metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.65 billion in 2025 and is expected to reach USD 2.35 billion by 2032. Another estimate for the global mTNBC market is USD 1.66 billion in 2025, growing to USD 2.73 billion by 2035. In the 7MM, the market size for triple-negative breast cancer was found to be USD 4.5 billion in 2024, with the United States accounting for approximately 69% of this market.
• Sabizabulin for metastatic castration and androgen receptor targeting agent resistant prostate cancer: The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market size was valued at USD 21.04 billion in 2025, projected to grow to USD 29.08 billion in 2026 and USD 91.85 billion by 2034. The 7MM metastatic castration-resistant prostate cancer markets reached a value of USD 7.2754 billion in 2024.
• VERU-100 for advanced hormone sensitive prostate cancer: The global Hormone Sensitive Advanced Prostate Cancer Treatment Market is estimated to be valued at USD 14.3 billion in 2025 and is projected to reach USD 28.7 billion by 2035. The Hormone-Sensitive Prostate Cancer Market is projected to reach USD 29.61 billion by 2035 globally.
• Zuclomiphene Citrate for hot flashes: The global menopausal hot flashes market size was valued at USD 8.09 billion in 2025. Other estimates for the global menopausal hot flashes treatment market include USD 6.9 billion in 2024, projected to reach USD 11.5 billion by 2035, and USD 8.76 billion in 2024, projected to grow to USD 16.22 billion by 2034.
• Sabizabulin for SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome: The global Acute Respiratory Distress Syndrome (ARDS) market size is expected to grow from USD 980.4 million in 2021 to USD 2.1376 billion by 2030. In 2023, the Acute Respiratory Distress Syndrome market size in the US was approximately USD 1.643 billion. The 7 major severe acute respiratory syndrome coronavirus infection markets have reached a value of USD 23.8 billion in 2024.
• New drug formulation for lower urinary tract symptoms from an enlarged prostate: The global benign prostatic hyperplasia (BPH) treatment market size was valued at USD 13.0 billion in 2025, expected to reach USD 18.9 billion by 2034. Another source estimates the global market size at USD 12.49 billion in 2024, projected to increase to USD 21.46 billion by 2034.

AI Analysis | Feedback

Veru Inc. (VERU) anticipates future revenue growth over the next 2-3 years to be driven by the advancement and potential commercialization of several key drug candidates in its pipeline.

• Commercialization of Enobosarm in combination with GLP-1 receptor agonists for high-quality weight loss: Veru is strategically focusing on developing Enobosarm to be combined with GLP-1 receptor agonists to prevent muscle loss and augment fat loss in overweight and obese patients. The company initiated a Phase 2b clinical study for this combination in April 2024, with top-line results expected by the end of calendar year 2024. More recently, Veru enrolled the first patient in its Phase 2b PLATEAU clinical trial for the Enobosarm and Semaglutide combination, with interim results anticipated in Q1 2027.

• Regulatory approval and commercial launch of Enobosarm for AR+ ER+ HER2- metastatic breast cancer: Enobosarm, an oral selective androgen receptor agonist, is currently in a Phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer.

• Regulatory approval and commercial launch of Sabizabulin for oncology indications: Sabizabulin, an oral cytoskeleton disruptor, is a lead product candidate in pivotal trials. It is in Phase II clinical trials for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer and metastatic triple-negative breast cancer.

• Regulatory approval and commercial launch of Sabizabulin for SARS-CoV-2 induced acute respiratory distress syndrome (ARDS): Sabizabulin is also undergoing a Phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome.

AI Analysis | Feedback

Share Repurchases

No information available regarding share repurchases made or authorized by Veru Inc. over the last 3-5 years.

Share Issuance

• Veru Inc. completed an underwritten public offering on October 31, 2025, which included shares of common stock and warrants, generating approximately $23.4 million in net proceeds.
• In December 2023, the company raised approximately $35.2 million through public offerings.
• Shareholders approved an amendment to the 2018 Equity Incentive Plan on March 12, 2026, increasing the number of common shares authorized for issuance for equity awards from 2,600,000 to 5,850,000.

Inbound Investments

No information available regarding large inbound investments made in the company by third-parties over the last 3-5 years, beyond capital raised through public offerings.

Outbound Investments

• Veru Inc. sold its FC2 Female Condom business on December 30, 2024 (fiscal year 2025), for $18 million.
• During fiscal year 2025, the company sold its ENTADFI assets for $20 million, recognizing a gain of $10.8 million.

Capital Expenditures

• Research and development expenses were $15.6 million in fiscal year 2025, an increase from $12.8 million in fiscal 2024, primarily driven by ongoing clinical studies.
• Research and development costs significantly decreased to $1.3 million in the first quarter of fiscal 2026 from $5.7 million in the first quarter of fiscal 2025, due to the wind-down of the Phase 2b QUALITY clinical study.
• Net proceeds from the October 2025 public offering are designated to fund the development of enobosarm, with a primary focus on the Phase 2b PLATEAU clinical study activities.